Improved Survival With Statins, Angiotensin Receptor Blockers, and Steroid Weaning After Heart Transplantation

Transplantation Proceedings

Volumn 38, Issue 5, 2006, Pages 1501-1506

  Lubitz, S A ^a   Baran, D A ^b   Alwarshetty, M M ^b   Zucker, M J ^b   Arroyo, L H ^b   Chan, M ^a   Courtney, M C ^a   Correa, R ^a   Spielvogel, D ^a   Lansman, S L ^a   Gass, A L ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CREATININE; CYCLOSPORIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEGRO; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CAUSE OF DEATH; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; RECEPTORS, ANGIOTENSIN; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745183288     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2006.02.131     Document Type: Article

References (22)

1. Taylor D.O., Edwards L.B., Boucek M.M., et al. The Registry of the International Society for Heart and Lung Transplantation. twenty-first official adult heart transplant report-2004. J Heart Lung Transplant 23 (2004) 796
2. Baran D.A., Galin I.D., and Gass A.L. Current practices. immunosuppression induction, maintenance, and rejection regimens in contemporary post-heart transplant patient treatment. Curr Opin Cardiol 17 (2002) 165
3. Kobashigawa J., Miller L., Renlund D., et al., Mycophenolate Mofetil Investigators. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66 (1998) 507
4. Wenke K., Meiser B., Thiery J., et al. Simvastatin initiated early after heart transplantation. 8-year prospective experience. Circulation 107 (2003) 93
5. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 (1995) 621
6. Mehra M.R., Uber P.A., Vivekananthan K., et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 40 (2002) 1609
7. Baran D.A., Segura L., Kushwaha S., et al. Tacrolimus monotherapy in adult cardiac transplant recipients. intermediate-term results. J Heart Lung Transplant 20 (2001) 59
8. Billingham M.E., Cary N.R., Hammond M.E., et al., The International Society for Heart Transplantation. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. Heart Rejection Study Group. J Heart Transplant 9 (1990) 587
9. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31
10. Taylor D.O., Edwards L.B., Mohacsi P.J., et al. The registry of the International Society for Heart and Lung Transplantation. twentieth official adult heart transplant report-2003. J Heart Lung Transplant 22 (2003) 616
11. Mehra M.R., Ventura H.O., Smart F.W., et al. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol 75 (1995) 853
12. Schroeder J.S., Gao S.Z., Alderman E.L., et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 328 (1993) 164
13. Mehra M.R., Uber P.A., Scott R.L., et al. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. Transplantation 74 (2002) 1568
14. Halcox J.P., and Deanfield J.E. Beyond the laboratory. clinical implications for statin pleiotropy. Circulation 109 suppl 1 (2004) 1142
15. Givertz M.M. Manipulation of the renin-angiotensin system. Circulation 104 (2001) E14
16. Richter M.H., Richter H., Barten M., et al. Angiotensin II type I receptor blockade after cardiac transplantation reduced the incidence and severity of transplant vasculopathy in an animal-based study. Transplant Proc 34 (2002) 1484
17. Paul L.C. Calcium channel blockers and angiotensin-converting enzyme inhibitors in the prevention of graft vasculopathy. J Heart Lung Transplant 19 (2000) 409
18. Opelz G., Dohler B., and Laux G. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 5 (2005) 720
19. Taylor D.O., Bristow M.R., O'Connell J.B., et al. Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy. J Heart Lung Transplant 15 (1996) 1039
20. Felkel T.O., Smith A.L., Reichenspurner H.C., et al. Survival and incidence of acute rejection in heart transplant recipients undergoing successful withdrawal from steroid therapy. J Heart Lung Transplant 21 (2002) 530
21. Olivari M.T., Jessen M.E., Baldwin B.J., et al. Triple-drug immunosuppression with steroid discontinuation by six months after heart transplantation. J Heart Lung Transplant 14 (1995) 127
22. Lindenfeld J., Page II R.L., Zolty R., et al. Drug therapy in the heart transplant recipient: part III: common medical problems. Circulation 111 (2005) 113